1-(4-chlorophenylamino)-4-(2-methylaminocarbonyl-pyridin-4-ylmethyl)isoquinoline | 332012-39-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1-(4-chlorophenylamino)-4-(2-methylaminocarbonyl-pyridin-4-ylmethyl)isoquinoline
• 英文别名: 1-(4-chlorophenylamino)-4-(2-methylaminocarbonyl-4-pyridylmethyl)-isoquinoline；4-[[1-(4-chloroanilino)isoquinolin-4-yl]methyl]-N-methylpyridine-2-carboxamide
• CAS: 332012-39-2
• 化学式: C₂₃H₁₉ClN₄O
• 分子量: 402.883
• InChiKey: NTZYWVGVUJTLIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  66.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY<br/>[FR] PYRIDINES ET PYRIDAZINES SUBSTITUEES A ACTIVITE INHIBITRICE DE L'ANGIOGENESE
  申请人：BAYER AG

  公开号：WO2001023375A2

  公开（公告）日：2001-04-05

  Substituted pyridines and pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R?1 and R2¿ may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

  具有抑制血管生成活性的取代吡啶和吡嗪的一般结构式（I），其中包含A、B、D、E和L的环是苯基或含氮的杂环；X和Y基团可以是各种定义的连接单元之一；R1和R2可以是独立定义的取代基，也可以一起定义一个环桥；环J可以是芳基、吡啶基或环烷基团；G基团可以是各种定义的取代基。还公开了含有这些物质的药物组合物以及使用这些物质治疗具有异常血管生成或高渗透性过程的哺乳动物的方法。
• Substituted pyridines and pyridazines with angiogenesis inhibiting activity
  申请人：Bayer Pharmaceuticals Corporation

  公开号：US20040092740A1

  公开（公告）日：2004-05-13

  Substituted and pyridines and pyridazines having angiogenesis inhibiting activity and the generalized structural formula 1 wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R 1 and R 2 may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.

  具有抑制血管生成活性的取代的吡啶和吡啶并，其广义结构式1如下：其中包含A、B、D、E和L的环是苯基或含氮杂环；X和Y基团可以是各种定义的连接单元之一；R1和R2可以是独立定义的取代基，或者一起可以是环定义的桥；环J可以是芳基、吡啶基或环烷基；G基团可以是各种定义的取代基。还公开了含有这些物质的药物组合物，并使用这些物质治疗具有异常血管生成或过度通透性过程特征的哺乳动物的方法。
• COMPOUNDS FOR TREATING PULMONARY HYPERTENSION
  申请人：Klein Martina

  公开号：US20100113452A1

  公开（公告）日：2010-05-06

  The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

  本发明涉及用于治疗、预防或管理肺动脉高压的制药组合物和组合物，包括小分子杂环类药物，特别是取代的吡啶和吡啶二氮杂环，可选地与至少一种其他治疗剂联合使用。
• SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY
  申请人：BAYER CORPORATION

  公开号：EP1228063B1

  公开（公告）日：2009-02-11
• US6689883B1
  申请人：——

  公开号：US6689883B1

  公开（公告）日：2004-02-10